Our Philosophy

At Lifeon, we are committed to enhancing clinical value through advanced drug delivery technologies. Our core focus lies in the development of osmotic pump-controlled release formulations, a platform we leverage to drive a differentiated product strategy and deliver superior therapeutic outcomes.

Facilities & Infrastructure

Lifeon’s R&D center, pilot plant, and GMP-compliant manufacturing facilities are fully equipped to support sophisticated chemical reactions under specialized conditions — including high pressure, low and high temperatures, anhydrous (无水), anaerobic (无氧), and high-vacuum (高真空) environments. These capabilities enable us to perform seamless transitions from R&D through scale-up to commercial production. 

To date, we have successfully developed and produced dozens of high-value APIs and critical pharmaceutical intermediates.

R&D Focus Areas

Complex API synthesis for high-barrier molecules

Semi-synthetic pathways for natural products

Extraction and separation of botanical active compounds

Osmotic pump-controlled oral drug delivery technology

Long-acting and targeted injectable delivery systems

Fully human monoclonal antibody-fusion protein platforms for oncology 

Osmotic Pump Drug Delivery Technology

Lifeon has developed a proprietary platform for osmotic pump-controlled release formulations. These dosage forms feature a drug core enclosed in a semi-permeable membrane, with drug release driven by osmotic pressure gradients. This design ensures controlled, predictable release kinetics and minimizes the influence of gastrointestinal pH and motility, offering improved consistency and patient outcomes. 

Today, Lifeon is one of the most advanced and scaled producers of osmotic pump products in China. 

TCM Extraction Platform: Ring-Type Percolation System

In collaboration with Tsinghua University, Lifeon developed China’s first continuous-processing extraction platform for traditional Chinese medicine (TCM), based on the “membrane-disruption and wall-rupture / ring-type percolation” model (破壁破膜–环型浸出). 

This innovative platform combines mechanical disruption of plant cell walls and membranes with a ring-type countercurrent extraction unit, resulting in: 

Significantly reduced extraction time 

Higher extraction yields 

Continuous and scalable TCM production 

The system represents a technological leap in modernizing TCM manufacturing. 

Fully Human Monoclonal Antibody-Fusion Protein Platform

Leveraging phage display technology, Lifeon has established a robust screening platform for fully human monoclonal antibodies with high affinity and broad tumor-targeting capabilities. These antibodies are then fused with potent bioactive cytokines to generate next-generation antibody-cytokine fusion proteins for oncology applications. 

This platform enables the development of multiple tumor-targeted biologics with enhanced precision and therapeutic efficacy. 

Collaborative Innovation Ecosystem

Lifeon maintains long-term R&D partnerships with leading institutions, including the University of Science and Technology of China and Tsinghua University. Leading academics in chemistry and drug delivery serve as senior scientific advisors to the company. We also collaborate widely with universities and research institutes across China, forming a tightly integrated innovation network that fuels our technology-driven growth.